Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drug and Alcohol Dependence|August 23, 2008
Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV)Stephen F Butler, José Pedro Redondo, Kathrine C Fernandez, et al.
Journal of Nutrition Education and Behavior|May 7, 2008
A pilot study of an online workplace nutrition program: the value of participant input in program developmentTara Cousineau, Brian Houle, Jonas Bromberg, et al.
Journal of Addiction Medicine|February 18, 2010
Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R)Stephen F Butler, Simon H Budman, Kathrine C Fernandez, et al.
Pain Medicine (Malden, Mass.)|December 17, 2009
Measuring attractiveness for abuse of prescription opioidsStephen F Butler, Kathrine C Fernandez, Alan Chang, et al.
Pain|May 12, 2007
Development and validation of the Current Opioid Misuse MeasureStephen F Butler, Simon H Budman, Kathrine C Fernandez, et al.
Harm Reduction Journal|February 7, 2006
Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusersStephen F Butler, Christine Benoit, Simon H Budman, et al.
Pain Medicine (Malden, Mass.)|June 21, 2008
Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administratorsNathaniel Katz, Brian Houle, Kathrine C Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell CarcinomaJean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Pageof 2